The National Health Commission said on July 20 that 24 COVID-19 patients were discharged from hospitals after recovery on the Chinese mainland on July 19.
Beijing has been cleared of medium-risk areas for COVID-19, with the last medium-risk area being downgraded to the low-risk category, a municipal health commission official said on July 20.
Chinese health authority said on July 19 that it received reports of 16 new confirmed COVID-19 cases on the Chinese mainland on July 18, of which 13 were domestically transmitted.
Beijing will lower its emergency response to COVID-19 from level II to III starting on July 20, announced an official of the Beijing municipal government at a press conference on July 19.
Chinese health authority said on July 16 that it received reports of no new domestically transmitted COVID-19 cases but one imported case on the Chinese mainland on July 15.
Beijing reported no new confirmed domestically transmitted COVID-19 cases on July 14, the municipal health commission said on July 15.
Special vehicle fleets will be built for high-risk pre-hospital medical missions, such as transferring COVID-19 patients, to reduce the risks of virus transmission and cross infection between patients and medics during transfer.
Beijing on July 13 lowered its COVID-19 risk level of more areas as the Chinese capital city was cleared of high-risk areas for the disease, according to local authorities.
Beijing reported no new confirmed domestically transmitted COVID-19 cases on July 11, the municipal health commission said July 12.
Beijing on July 8 reported no new confirmed domestically transmitted cases of COVID-19, the municipal health commission said on July 9.
China plans to support international cooperation research projects on drugs, vaccines, test kits, and traditional Chinese medicine to fight COVID-19.
More than 11 million people in Beijing have been given nucleic acid tests since the resurgence of domestically transmitted COVID-19 cases in June, local authorities said on July 6.
Beijing had reported single-digit COVID-19 cases for seven consecutive days by July 4, local authorities said on July 5.
Sinopharm Group is speeding up development of a candidate vaccine for the novel coronavirus that causes COVID-19, with more milestones having been achieved by the Chinese State-owned pharmaceutical giant ahead of hoped-for mass production.
China has requested its medical institutions to cut the turnaround time for COVID-19 nucleic acid test results to a maximum of 24 hours, according to an official circular released on July 2.
Nearly 20 residential communities in Beijing have lowered their risk level for COVID-19 control and prevention as the city has taken effective measures to contain the spread of the outbreak, a senior official said on July 1.
Chinese health authority said on June 30 it received reports of 19 newly confirmed COVID-19 cases on the Chinese mainland on June 29, including eight domestically transmitted and 11 imported ones.
Beijing has boosted its nucleic acid testing capability for novel coronavirus infection by adopting new equipment and high-level technologies, with the capital completing tests for about 7.7 million people by June 28.
Medical staff members take throat swab samples from people at a newly-adopted mobile testing vehicle in Xicheng district of Beijing, capital of China, June 28, 2020.